Journal ArticleDOI
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Reads0
Chats0
TLDR
Assessing long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration patients found one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes.About:
This article is published in Ophthalmology.The article was published on 2013-11-01. It has received 821 citations till now. The article focuses on the topics: Ranibizumab & Macular degeneration.read more
Citations
More filters
Journal ArticleDOI
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Michiko Mandai,Akira Watanabe,Yasuo Kurimoto,Yasuhiko Hirami,Chikako Morinaga,Takashi Daimon,Masashi Fujihara,Hiroshi Akimaru,Noriko Sakai,Yumiko Shibata,Motoki Terada,Yui Nomiya,Shigeki Tanishima,Masahiro Nakamura,Hiroyuki Kamao,Sunao Sugita,Akishi Onishi,Tomoko Ito,Kanako Fujita,Shin Kawamata,Masahiro J. Go,Chikara Shinohara,Kenichiro Hata,Masanori Sawada,Midori Yamamoto,Sachiko Ohta,Yasuo Ohara,Kenichi Yoshida,Junko Kuwahara,Yuko Kitano,Naoki Amano,Masafumi Umekage,Fumiyo Kitaoka,Azusa Tanaka,Chihiro Okada,Naoko Takasu,Seishi Ogawa,Shinya Yamanaka,Masayo Takahashi +38 more
TL;DR: At 1 year after surgery, the transplanted sheet of retinal pigment epithelial cells remained intact, best corrected visual acuity had not improved or worsened, and cystoid macular edema was present.
Journal ArticleDOI
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire,Daniel F. Martin,Gui-Shuang Ying,Glenn J. Jaffe,Ebenezer Daniel,Juan E. Grunwald,Cynthia A. Toth,Frederick L. Ferris,Stuart L. Fine +8 more
TL;DR: Vision gains during the first 2 years were not maintained, but 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.
Journal ArticleDOI
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz,Ramin Tadayoni,Stephen Beatty,Alan R. Berger,Matteo Giuseppe Cereda,Rafael Cortez,Carel B. Hoyng,Philip G Hykin,Giovanni Staurenghi,Stephanie Heldner,Timon Bogumil,Theresa Heah,Sobha Sivaprasad +12 more
TL;DR: Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time and in clinical practice, fewer injections are administered than in clinical trials.
Journal ArticleDOI
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth,Victor Chong,Anat Loewenstein,Michael Larsen,Eric H Souied,Reinier O. Schlingemann,Bora Eldem,Jordi Monés,Gisbert Richard,Francesco Bandello +9 more
TL;DR: Ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up, but definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management.
Journal ArticleDOI
Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.
Sandra Schoors,Katrien De Bock,Anna Rita Cantelmo,Maria Georgiadou,Bart Ghesquière,Sandra Cauwenberghs,Anna Kuchnio,Brian W. Wong,Annelies Quaegebeur,Jermaine Goveia,Francesco Bifari,Xingwu Wang,Raquel Blanco,Bieke Tembuyser,Ivo Cornelissen,Ann Bouché,Stefan Vinckier,Santiago Diaz-Moralli,Holger Gerhardt,Holger Gerhardt,Sucheta Telang,Marta Cascante,Jason Chesney,Mieke Dewerchin,Peter Carmeliet +24 more
TL;DR: Although 3PO reduced glycolysis only partially and transiently in vivo, this sufficed to decrease pathological neovascularization in ocular and inflammatory models and may offer therapeutic antiangiogenic opportunities.
References
More filters
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F. Martin,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Stuart L. Fine,Glenn J. Jaffe +5 more
TL;DR: Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Journal ArticleDOI
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F. Martin,Maureen G. Maguire,Stuart L. Fine,Gui-Shuang Ying,Glenn J. Jaffe,Juan E. Grunwald,Cynthia A. Toth,Maryann Redford,Frederick L. Ferris +8 more
TL;DR: Ranibizumab and bevacizumAB had similar effects on visual acuity over a 2-year period and switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2.
Related Papers (5)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more